311 related articles for article (PubMed ID: 35165857)
1. Antibody Therapies in Autoimmune Neuromuscular Junction Disorders: Approach to Myasthenic Crisis and Chronic Management.
Vanoli F; Mantegazza R
Neurotherapeutics; 2022 Apr; 19(3):897-910. PubMed ID: 35165857
[TBL] [Abstract][Full Text] [Related]
2. Myasthenia gravis: the role of complement at the neuromuscular junction.
Howard JF
Ann N Y Acad Sci; 2018 Jan; 1412(1):113-128. PubMed ID: 29266249
[TBL] [Abstract][Full Text] [Related]
3. Efgartigimod Alfa in Generalised Myasthenia Gravis: A Profile of Its Use.
Heo YA
CNS Drugs; 2023 May; 37(5):467-473. PubMed ID: 37000339
[TBL] [Abstract][Full Text] [Related]
4. Monoclonal Antibody-Based Therapies for Myasthenia Gravis.
Alabbad S; AlGaeed M; Sikorski P; Kaminski HJ
BioDrugs; 2020 Oct; 34(5):557-566. PubMed ID: 32915379
[TBL] [Abstract][Full Text] [Related]
5. Role of complement, anti-complement therapeutics, and other targeted immunotherapies in myasthenia gravis.
Dalakas MC
Expert Rev Clin Immunol; 2022 Jul; 18(7):691-701. PubMed ID: 35730504
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic Monoclonal Antibody Therapies in Chronic Autoimmune Demyelinating Neuropathies.
Briani C; Visentin A
Neurotherapeutics; 2022 Apr; 19(3):874-884. PubMed ID: 35349079
[TBL] [Abstract][Full Text] [Related]
7. Receptor clustering and pathogenic complement activation in myasthenia gravis depend on synergy between antibodies with multiple subunit specificities.
Rose N; Holdermann S; Callegari I; Kim H; Fruh I; Kappos L; Kuhle J; Müller M; Sanderson NSR; Derfuss T
Acta Neuropathol; 2022 Nov; 144(5):1005-1025. PubMed ID: 36074148
[TBL] [Abstract][Full Text] [Related]
8. Starting eculizumab as rescue therapy in refractory myasthenic crisis.
Vinciguerra C; Bevilacqua L; Toriello A; Iovino A; Piscosquito G; Calicchio G; Barone P
Neurol Sci; 2023 Oct; 44(10):3707-3709. PubMed ID: 37306795
[TBL] [Abstract][Full Text] [Related]
9. Overcoming therapeutic challenges: Successful management of a supposedly triple seronegative, refractory generalized myasthenia gravis patient with efgartigimod.
Sorrenti B; Laurini C; Bosco L; Strano CMM; Scarlato M; Gastaldi M; Filippi M; Previtali SC; Falzone YM
Eur J Neurol; 2024 Jul; 31(7):e16306. PubMed ID: 38716750
[TBL] [Abstract][Full Text] [Related]
10. Eye muscle antibodies in patients with ocular myasthenia gravis: possible mechanism for eye muscle inflammation in acetylcholine-receptor antibody-negative patients.
Gunji K; Skolnick C; Bednarczuk T; Benes S; Ackrell BA; Cochran B; Kennerdell JS; Wall JR
Clin Immunol Immunopathol; 1998 Jun; 87(3):276-81. PubMed ID: 9646837
[TBL] [Abstract][Full Text] [Related]
11. [Myasthenia in adults, children, and adolescents: what's new?].
Stascheit F; Della Marina A; Meisel A
Nervenarzt; 2023 Jun; 94(6):501-509. PubMed ID: 36995386
[TBL] [Abstract][Full Text] [Related]
12. Novel treatment strategies for acetylcholine receptor antibody-positive myasthenia gravis and related disorders.
Mané-Damas M; Molenaar PC; Ulrichts P; Marcuse F; De Baets MH; Martinez-Martinez P; Losen M
Autoimmun Rev; 2022 Jul; 21(7):103104. PubMed ID: 35452851
[TBL] [Abstract][Full Text] [Related]
13. A bioassay for neuromuscular junction-restricted complement activation by myasthenia gravis acetylcholine receptor antibodies.
Plomp JJ; Huijbers MGM; Verschuuren JJGM; Borodovsky A
J Neurosci Methods; 2022 May; 373():109551. PubMed ID: 35247492
[TBL] [Abstract][Full Text] [Related]
14. Abdeg technology for the treatment of myasthenia gravis: efgartigimod drug experience.
Dos Santos JBR; Gomes RM; da Silva MRR
Expert Rev Clin Immunol; 2022 Sep; 18(9):879-888. PubMed ID: 35892247
[TBL] [Abstract][Full Text] [Related]
15. Zilucoplan: An Investigational Complement C5 Inhibitor for the Treatment of Acetylcholine Receptor Autoantibody-Positive Generalized Myasthenia Gravis.
Howard JF; Vissing J; Gilhus NE; Leite MI; Utsugisawa K; Duda PW; Farzaneh-Far R; Murai H; Wiendl H
Expert Opin Investig Drugs; 2021 May; 30(5):483-493. PubMed ID: 33792453
[TBL] [Abstract][Full Text] [Related]
16. An update of the pharmacological treatment options for generalized myasthenia gravis in adults with anti-acetylcholine receptor antibodies.
Riley TR; Douglas JS; Wang C; Bowser KM
Am J Health Syst Pharm; 2023 May; 80(11):652-662. PubMed ID: 36775959
[TBL] [Abstract][Full Text] [Related]
17. Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis.
Howard JF; Bril V; Burns TM; Mantegazza R; Bilinska M; Szczudlik A; Beydoun S; Garrido FJRR; Piehl F; Rottoli M; Van Damme P; Vu T; Evoli A; Freimer M; Mozaffar T; Ward ES; Dreier T; Ulrichts P; Verschueren K; Guglietta A; de Haard H; Leupin N; Verschuuren JJGM;
Neurology; 2019 Jun; 92(23):e2661-e2673. PubMed ID: 31118245
[TBL] [Abstract][Full Text] [Related]
18. Efgartigimod improves muscle weakness in a mouse model for muscle-specific kinase myasthenia gravis.
Huijbers MG; Plomp JJ; van Es IE; Fillié-Grijpma YE; Kamar-Al Majidi S; Ulrichts P; de Haard H; Hofman E; van der Maarel SM; Verschuuren JJ
Exp Neurol; 2019 Jul; 317():133-143. PubMed ID: 30851266
[TBL] [Abstract][Full Text] [Related]
19. [Eculizumab Treatment for Refractory Generalized Myasthenia Gravis].
Uzawa A; Kuwabara S
Brain Nerve; 2019 Jun; 71(6):565-570. PubMed ID: 31171753
[TBL] [Abstract][Full Text] [Related]
20. Pharmacotherapy of Generalized Myasthenia Gravis with Special Emphasis on Newer Biologicals.
Menon D; Bril V
Drugs; 2022 Jun; 82(8):865-887. PubMed ID: 35639288
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
